OtriMed Clinical Research is pleased to have participated in the trials which led to the approval of this breakthrough treatment.
We are currently enrolling teens with post-partum depression to participate in a similar study, with no cost to qualifying candidates. Contact us at (859) 757-1359 for more details.
On March 19, 2019, the U.S. Food and Drug Administration (FDA) approved ZULRESSO (brexanolone) for the treatment of postpartum depression (PPD) in adults. The approved recommended dosage of ZULRESSO administered as a continuous intravenous infusion over 60 hours is as ...
Postpartum Depression (PPD) is a serious mood disorder. It is estimated that, in the United States, depending on states, the incidence varies from 10 – 20%. PPD poses serious risk to the mother and the new born. PPD IS A MAJOR CAUSE OF MATERNAL MORTALITY. It affects maternal functioning and causes significant risk to the cognitive, behavioral and physical development of the infant and siblings.
Currently the standard of care for PPD is the same treatment that is offered to manage Major Depressive disorder. Although SSRI are effective for Major depressive ...
